EBIT: Income before interest and taxes.
X4 Pharmaceuticals, Inc. (XFOR) had EBIT of $-86.88M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$35.11M |
|
$-79.20M |
|
$5.76M |
|
$29.36M |
|
$122.00M |
|
$-86.88M |
|
$7.72M |
|
$-79.16M |
|
$-79.16M |
|
$-79.20M |
|
$-79.20M |
|
$-79.20M |
|
$-79.20M |
|
|
EBIT |
$-86.88M |
$-85.61M |
|
42.29M |
|
42.29M |
|
$-1.87 |
|
$-1.87 |
|
| Balance Sheet Financials | |
$261.58M |
|
$0.18M |
|
$28.88M |
|
$290.46M |
|
$25.76M |
|
$76.29M |
|
$78.41M |
|
$104.17M |
|
$186.29M |
|
$159.69M |
|
$186.29M |
|
90.91M |
|
| Cash Flow Statement Financials | |
$-85.62M |
|
$8.15M |
|
$238.63M |
|
$56.48M |
|
$217.85M |
|
$161.38M |
|
$4.30M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
10.16 |
|
-- |
|
-- |
|
0.29 |
|
0.41 |
|
83.60% |
|
-247.44% |
|
-247.44% |
|
-243.80% |
|
-225.44% |
|
-225.55% |
|
$-85.62M |
|
-- |
|
-- |
|
-- |
|
0.12 |
|
1.29 |
|
61.28 |
|
5.96 |
|
-42.51% |
|
-49.60% |
|
-27.27% |
|
-30.16% |
|
$2.05 |
|
$-2.02 |
|
$-2.02 |
|